Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China

Jin Shi, Daojuan Li, Di Liang & Yutong He

To explore the epidemiological characteristics and prognosis of lung cancer in patients aged under 45 years old in northern China. The population-based database about lung cancer cases aged under 45y selected form the Hebei Provincial Cancer Registry Center from 2010–2015. Mortality data of young death from 1973 to 1975, 1990 to 1992, and 2004 to 2005 were extracted from the national retrospective survey of death. Mortality rates were calculated by the mortality database above in this analysis. Consecutive, 954 non-selected younger patients (<45 years) and 2261 selected older patients (≥45 years) with pathologically diagnosed lung cancer treated at the Fourth Hospital of Hebei Medical University were included as the hospital-based database. Epidemiological, treatment outcomes and prognosis status from 2010 to 2017 were documented. A comparison with younger and older patients was also made. Multivariate analysis with young lung cancer patients was calculated by Cox regression model. The younger lung cancer mortality rate tended to slightly increase in Hebei Province, from 1.04 per 100 000 in 1973 to 2.01 per 100 000 in 2015, but the PDR tended to decrease over the last 40 years. There were 954 younger and 2261 older lung cancer patients included in the hospital-based database. The proportions of patients who were female (50.84% vs 34.85%), family history of cancer (12.37% vs 6.32%), advanced stage at diagnosis (65.46% vs 60.77%) and adenocarcinoma (65.27% vs 61.11%) were relatively higher in the younger group than in the older group. The median OS were 23.0 months and 27.0 months between younger and older, the OS difference existed between the two groups (P = 0.001). In the younger patients, Cox regression showed that a family history of cancer, symptoms at diagnosis, pathology, stage at diagnosis and surgery were confirmed as independent factors affecting the prognosis. Mortality rates among younger lung cancer patients showed an increasing trend in northern China. The younger account for small but have unique characteristics, with higher proportions of female, family history of cancer, adenocarcinoma and advanced stages than the older group and had a trend of worse OS.

Lung cancer, which has a variety of histological subtypes, is a multi-step and multi-factorial disease. According to GLOBOCAN 2018, there were approximately 2.1 million new lung cancer cases and 1.8 million lung cancer-related deaths worldwide. In China, lung cancer is the most common cancer and a major cause of cancer-related death disease, and in the last ten years, the incidence rate has increased 12.16%. Although an analysis of 17 population-based registries showed that the survival rate in lung cancer patients had increased from 16.1% in 2003–2005 to 19.7% in 2012–2015, the prognosis remains very poor, and lung cancer poses a serious threat to human health in China. Hebei Province, located in northern China, has one of the highest incidence rates of lung cancer, with an incidence rate that is 1.10-fold than the national rate. Lung cancer is predominantly identified in the relatively older population; therefore, several international organizations have suggested that to discover more cases of lung cancer in the early stage, when they could be cured, the age at which lung cancer screening should start is 55–74 years in the USA and 50–74 years in China. However, the smaller but not insignificant proportion of younger patients should not be ignored.

Lung cancer is relatively rare in the younger population, and less than 3.5% of lung cancer patients are younger than 45 years old. However, in recent decades, as the incidence of lung cancer has increased, the average age at diagnosis has decreased. Lung cancer in young patients is a poorly studied clinical entity, and only a few
studies have described the risk factors for and clinical characteristics, incidence, mortality and outcomes of lung cancer in this population. In addition, the results of previous research on lung cancer in younger patients are not completely consistent. On the one hand, the results consistently suggested that lung cancer cases in young patients may constitute a clinical entity with distinct clinical and pathological characteristics, with fewer patients who were smokers, more female patients, a predominance of adenocarcinoma and a more advanced stage at initial diagnosis. On the other hand, the proportions of patients with mutations in the epidermal growth factor receptor (EGFR), a family history of cancer and a poor prognosis differed among reports.

Written informed consent was obtained from all subjects or from their next of kin if the patients were deceased. Guidelines. Written informed consent was obtained from all subjects or from their next of kin if the patients were deceased. In the mid-1970s, a nationwide retrospective survey of the causes of mortality of 56 diseases (with a special emphasis on cancer), organized by the National Office for Cancer Prevention and Control, was conducted in 29 provinces, including Hebei Province. This survey covered all 153 cities and counties in Hebei Province. For the first time, it provided the national profiles and patterns of cancer mortality, as well as the total mortality rate in Hebei Province.

A national retrospective sampling survey of cancer mortality was organized in 1990–1992 by the National Office for Cancer Prevention and Control. This survey employed a stratified sampling method and covered approximately 10% of the Chinese. 21 regions in Hebei Province were enrolled. A retrospective survey of all death causes for the period was organized in China, 2004–2005. It was carried out in 31 provinces/municipalities/autonomous regions, including Hebei Province in China in 2006. A total of 18 cities and counties were selected as sampling areas, with a total population of 13,791,868 persons (20.2% of the total population of Hebei Province).

Population-based cancer registration data. The Hebei Provincial Cancer Registry Centre was established in 2009 and became the primary entity responsible for data collection starting in 2010. The latest data collected were from 2015. A total of 33 population-based cancer registries in Hebei Province submitted data from 2010 to 2015, and the data from 21 population-based cancer registries qualified for inclusion in the pooled data used in the final analysis. These cancer registries covered 50.28 million person-years, accounting for 11.5% of the population in Hebei Province.

Hospital-based young lung cancer cases. The Fourth Hospital of Hebei Medical University, also known as the Tumour Hospital of Hebei, is one of the largest and most comprehensive hospitals in Hebei. We collected all the data pertaining to 954 young patients diagnosed with lung cancer at the Fourth Hospital of Hebei Medical University between 1 January 2010 and 31 December 2017. Patients older than 45 years who were diagnosed with lung cancer were sampled as follows: those meeting the inclusion criteria were stratified by the month in which they were diagnosed, and the patients in each month were divided into ten groups based on a random number table. There were no significant differences in sex or age among the ten groups (P > 0.05). Then, we selected one number randomly from each group for inclusion in the analysis. Eventually, 2261 lung cancer patients older than 45 years were enrolled in the study. Age, sex, family history of cancer, smoking history, drinking history, height, weight, onset symptoms, tumour location, cancer stage at diagnosis, pathology, serum biomarkers, EGFR mutation status, therapies and survival status were collected in detail.

Ethics statement. The use of the data from the lung cancer patients in the population-based and hospital-based cancer registries was approved by the Ethics Informed Committee of the Fourth Hospital of Hebei Medical University (Shijiazhuang, Hebei, China), and all analyses were performed in accordance with the approved guidelines. Written informed consent was obtained from all subjects or from their next of kin if the patients were deceased.

Follow-up. The date of death or the last follow-up date if the subject was still alive were also collected. The last follow-up date was December 31st, 2019. Overall survival (OS) was defined as the time from diagnosis to death from any cause, and patients who remained alive were censored at the end of the study. Censored subjects included patients who were lost to follow-up and those who had not experienced the outcome (death) before the end of the study period.

Statistical analysis. Using the data from the population-based database, the CMR (crude mortality rate), ASRW (age-standardized rate using the world standard population), ASRC (age-standardized rate using the China standard population (2000)), and PDR (proportional death rate) were calculated with SAS software.
Using the data from the hospital-based database, continuous variables were summarized as the means with standard deviations or medians with ranges; categorical variables were summarized as frequencies and percentages. Pearson’s chi-squared test was used to assess the significance of differences in categorical variables between the younger and the older. A Kaplan–Meier analysis was performed. Multivariable analyses were performed with a Cox proportional hazards model. All analyses were conducted using the SPSS for the Windows software system (version 21.0; IBM Corp, Armonk, NY, USA) (https://www.ibm.com/support/pages/node/213045) and the “survminer” and “forestplot” package in the software R3.1.3 (R Core Team, 2015) (https://mirrors.tuna.tsinghua.edu.cn/CRAN/). Statistical significance was determined by a two-tailed p value ≤ 0.05. Any missing values were reported as unknown, and thus, not all the study population was included in the different analyses.

Results
Trend in mortality trend among young lung cancer patients in Hebei Province in the population-based database, 1973–2015. As shown in Table 1 and Fig. 1, the lung cancer mortality rate in younger tended to slightly increase in Hebei Province from 1973 to 2015. In 1973–1975, the CMR was 1.04 per 100,000 (1.29 per 100,000 for males and 0.79 per 100,000 for females). It increased to 2.01 per 100,000 (2.40 and 1.59 per 100,000 for males and females) in 2010–2015. In 1973–1975, the ASRW in younger was 0.88 per 100,000, accounting for 8.73% of all lung cancer-related deaths. In 1990–1992, it was 1.17 per 100,000, accounting for 7.14%. The lung cancer ASRW was 1.08 per 100,000, with a PDR of 4.84% in 2004–2005. In 2010–2015, the ASRW was 1.02 per 100,000, with a PDR of 3.40%. The ASRW in 2010–2015 was 93.27% higher than in 1973–1975. During the study period, the ASRW increased in both men and women; in contrast, the PDR tended to decrease over the last 40 years, with 63.15% and 56.84% reductions in males and females, respectively. The PDR was higher in females than in males. In addition, the median age at death of young lung cancer patients was 38.80 years in 1973–1975, 38.77 years in 1990–1992, 39.44 years in 2004–2005 and 40.83 years in 2010–2015.

Characteristics of lung cancer patients in the hospital-based database. In total, 954 non-selected younger patients and 2261 randomly selected older patients were from the database of the Tumour Hospital of
| Items                     | ≤ 45 (N = 954) | > 45 (N = 2261) | X²    | P    |
|--------------------------|---------------|----------------|------|-----|
|                          | Total N       | Pro (%)        | Total N       | Pro (%)        |      |
| Gender                   |               |                |               |                |      |
| Male                     | 469           | 49.16          | 1473          | 65.15          |      |
| Female                   | 485           | 50.84          | 788           | 34.85          | 71.692 | 0.000 |
| Family history           | 954           | 2261           |                |                |      |
| Yes                      | 118           | 12.37          | 143           | 6.32           |      |
| No                       | 836           | 87.63          | 2118          | 93.68          | 32.861 | 0.000 |
| Smoking                  | 954           | 2261           |                |                |      |
| Yes                      | 275           | 28.83          | 1120          | 49.54          |      |
| No                       | 679           | 71.17          | 1141          | 50.46          | 117.146 | 0.000 |
| Drinking                 | 954           | 2261           |                |                |      |
| Yes                      | 290           | 30.40          | 933           | 41.26          |      |
| No                       | 663           | 69.50          | 1328          | 58.74          | 32.96  | 0.000 |
| BMI                      | 940           | 2211           |                |                |      |
| < 24.0                   | 499           | 53.09          | 1167          | 52.78          |      |
| > 24.0                   | 441           | 46.91          | 1004          | 47.22          | 0.024  | 0.876 |
| Symptoms at diagnosis    | 954           | 2261           |                |                |      |
| Yes                      | 773           | 81.03          | 1979          | 87.53          |      |
| No                       | 181           | 18.97          | 282           | 12.47          | 22.997 | 0.000 |
| Side                     | 906           | 2233           |                |                |      |
| Left                     | 390           | 40.88          | 1012          | 44.88          |      |
| Right                    | 516           | 54.82          | 1221          | 54.18          | 1.348  | 0.246 |
| Subside                  | 534           | 1556           |                |                |      |
| upper lobe               | 255           | 47.75          | 823           | 52.55          |      |
| Middle lobe              | 75            | 14.04          | 181           | 11.56          | 4.74   | 0.098 |
| Low lobe                 | 204           | 38.20          | 552           | 35.25          |      |
| Stage at diagnosis       | 718           | 1695           |                |                |      |
| I + II                   | 311           | 43.31          | 665           | 39.23          |      |
| III + IV                 | 470           | 65.46          | 1030          | 60.77          | 68.14  | 0.000 |
| Pathology                | 766           | 1764           |                |                |      |
| Adenocarcinoma           | 500           | 65.27          | 1078          | 61.11          |      |
| Squamous-cell carcinoma  | 77            | 10.05          | 434           | 24.60          |      |
| Small cell carcinoma     | 189           | 24.67          | 252           | 14.29          | 90.535 | 0.000 |
| CEA                      | 680           | 1185           |                |                |      |
| Normal                   | 387           | 56.91          | 685           | 57.81          |      |
| Abnormal                 | 293           | 43.09          | 500           | 42.19          | 0.14   | 0.707 |
| SCC                      | 469           | 866            |                |                |      |
| Normal                   | 397           | 84.65          | 728           | 84.06          |      |
| Abnormal                 | 72            | 15.35          | 138           | 15.94          | 0.08   | 0.780 |
| NSE                      | 649           | 793            |                |                |      |
| Normal                   | 324           | 49.92          | 449           | 56.62          |      |
| Abnormal                 | 325           | 50.08          | 344           | 43.38          | 6.44   | 0.010 |
| EGFR                     | 222           | 347            |                |                |      |
| Mutant                   | 109           | 49.10          | 154           | 44.81          |      |
| Nonmutant                | 113           | 50.90          | 192           | 55.19          | 1.146  | 0.284 |
| Surgery                  | 954           | 2261           |                |                |      |
| Yes                      | 302           | 31.66          | 1154          | 51.04          |      |
| No                       | 652           | 68.34          | 1107          | 48.96          | 81.61  | 0.000 |
| Radiotherapy             | 954           | 2261           |                |                |      |
| Yes                      | 249           | 26.10          | 472           | 20.88          |      |
| No                       | 705           | 73.90          | 1789          | 79.12          | 10.53  | 0.000 |
| Chemotherapy             | 954           | 2261           |                |                |      |
| Yes                      | 632           | 66.25          | 1370          | 60.59          |      |
| No                       | 322           | 33.75          | 891           | 39.41          | 9.13   | 0.000 |
| Targeted therapy         | 954           | 2261           |                |                |      |
| Yes                      | 81            | 8.49           | 129           | 5.71           |      |
| No                       | 873           | 91.51          | 2132          | 94.29          | 8.52   | 0.000 |

Table 2. The characteristics of lung cancer patients by hospital-based database.
Hebei Province from 2010 to 2017 for inclusion in this study. Patient characteristics in the younger and older groups are shown in Table 2.

The median age of the younger group was 40 years (range 19–45), while that of the older group was 61 years (range 46–88). The proportion of female patients was significantly higher in the younger group than in the older group (50.84% vs 34.85%, \( P < 0.001 \)). The ratio of patients with a family history of cancer was higher in the younger group than in the older group (12.37% vs 6.32%, \( P < 0.001 \)).

There were significant differences in the distribution of histological subtypes of lung cancer between the two groups (\( P < 0.001 \)). Adenocarcinoma was the most common histological subtype in both groups, but the younger group had a higher proportion with the adenocarcinoma. Squamous cell carcinoma was more common in the older group than in the younger group (24.60% vs 10.05%). In the younger group, SCLC was the second most common pathological type, but it ranked third in the older group (24.67% vs 14.29%). There were no statistically significant differences in either tumour sites or subsites between the groups (Table 2).

The distribution of stages was significantly different between the two groups. The younger group had a higher proportion of patients with advanced-stage disease at presentation than the older group (65.46% vs 60.77%, \( P < 0.001 \)). With regard to biomarkers, there were no significant differences in CEA and SCC in the two groups, but the proportion of patients with abnormal NSE was much higher in the younger group than in the older group (50.08% vs 43.38%, \( P = 0.01 \)). Among the lung cancer patients who were tested for EGFR gene mutations, the mutation rate in the younger group was higher than that in the older group, but the difference between the two groups was not significant (49.10% vs 44.81%, \( P = 0.284 \)). The results were shown as Table 2.

The proportions of patients who underwent surgery, radiotherapy, chemotherapy and targeted therapy were also analysed. Significantly higher proportions of patients in the younger group received chemotherapy and targeted therapy; in contrast, significantly higher proportions of patients in the older group underwent surgery and radiation therapy (\( P < 0.001 \)) (Table 2).

Survival analysis. Epidemiological factors affecting survival in lung cancer patients. In the hospital-based database, the median survival time for the entire population was 26.0 months, with survival durations of 23.0 months and 27 months in the younger group and older group, respectively. The 1-year, 3-year, and 5-year OS rates for the younger lung cancer patients were 68.58%, 36.86% and 27.14%, respectively. Among the older population, the rates were 75.11%, 41.83% and 30.82%, respectively. The survival rate in younger lung cancer patients was lower than that in those older than 45 years, with an HR of 0.829 (95% CI 0.747, 0.920). In the younger group, the median OS times were 21 months and 25 months for males and females, respectively. Female patients had a slightly better prognosis than males, and the difference was significant in univariate analysis (\( P = 0.002 \)) (Fig. 2). The same results were observed in the group of older lung cancer patients and the entire population (Table 3).

Regardless of group, the prognosis for smokers was much lower than that for never smokers, and the survival time for patients with symptoms at diagnosis was much lower than that for patients without symptoms at diagnosis. The median survival time was shorter for young lung cancer patients with a family history of cancer than for those without a family history of cancer (20 m vs 25 m, \( P = 0.012 \)) (Fig. 2, Table 3).
| Characteristic | ≤ 45 median survival month (95% CI) | > 45 median survival month (95% CI) | P value | Overall median survival month (95% CI) | P value | ≤ 45 median survival month (95% CI) | > 45 median survival month (95% CI) | P value |
|----------------|-------------------------------------|--------------------------------------|---------|--------------------------------------|---------|-------------------------------------|--------------------------------------|---------|
| Overall        | 23.0 (20.678,25.322)                | 27.0 (24.858,29.124)                |         | 26.0 (24.343,27.637)                | 0.001   |
| Sex            |                                     |                                      |         |                                      |         |                                     |                                      |         |
| Male           | 21.0 (17.614,24.384)                | 24.0 (21.679,26.321)                |         | 23.0 (21.215,24.785)                |         |
| Female         | 25.0 (21.108,28.894)                | 0.002 (38.0, 32.419,43.581)         | < 0.001 | 32.0 (27.937,36.063)                | < 0.001 |
| Family history | Yes 20.0 (19.709,23.291)            | 28.0 (25.620,30.380)                |         | 25.0 (21.674,28.326)                |         |
| No             | 25.0 (22.123,27.877)                | 0.012 (31.0, 20.612,41.388)         | 0.408   | 26.0 (24.674,27.867)                | 0.284   |
| Smoking        | Yes 19.0 (15.699,22.301)            | 24.0 (21.685,26.315)                |         | 23.0 (21.262,24.738)                |         |
| No             | 25.0 (21.507,28.493)                | 0.001 (35.0, 30.038,39.692)         | < 0.001 | 30.0 (26.724,33.276)                | < 0.001 |
| Drinking       | Yes 21.0 (16.014,25.966)            | 26.0 (22.970,29.030)                |         | 24.0 (21.692,26.531)                |         |
| No             | 25.0 (22.158,27.842)                | 0.427 (30.0, 26.424,33.576)         | 0.007   | 27.0 (24.826,29.174)                | 0.12    |
| BMI            | < 24.0 23.0 (20.508,25.492)         | 26.0 (23.066,28.934)                |         | 25.0 (23.017,26.983)                |         |
| > 24.0         | 25.0 (20.931,29.069)                | 0.357 (29.0, 25.952,32.048)         | 0.043   | 29.0 (26.198,31.802)                | 0.027   |
| Symptoms at diagnosis | Yes 22.0 (19.686,24.314) | 26.0 (23.945,28.055) | | 24.0 (22.599,25.401) | | No 39.0 (17.972,60.028) | < 0.001 | 52.0 (41.754,62.246) | < 0.001 |
| Site | Left 23.0 (18.733,27.267) | 25.0 (22.571,27.429) | | 24.0 (22.013,25.987) | | Right 25.0 (21.735,28.265) | 0.443 | 31.0 (27.006,34.994) | 0.007 |
| Subside | upper lobe 33.0 (25.807,40.193) | 43.0 (35.924,50.076) | | 41.0 (31.265,40.735) | | Middle lobe 15.0 (4.024,25.976) | | 58.0 (44.756,71.244) | | 42.0 (22.406,37.32) | | Low lobe 37.0 (24.367,49.633) | 0.174 | 44.0 (35.745,52.255) | 0.773 |
| Cancer stage at diagnosis | I + II 63.0 (40.487,85.513) | | | | | III + IV 18.0 (215.569,20.341) | < 0.001 | 19.0 (17.529,20.471) | < 0.001 |
| Pathology | SCCL 18.0 (12.791,23.209) | 16.0 (13.669,18.331) | | 19.0 (16.391,21.609) | | NSCLC 25.0 (22.182,27.782) | 0.034 | 31.0 (28.398,33.602) | < 0.001 |
| CEA | Normal 29.0 (23.543,34.457) | 27.0 (23.208,30.792) | | 28.0 (24.507,31.493) | | Abnormal 19.0 (16.680,21.320) | < 0.001 | 21.0 (18.709,23.231) | < 0.001 |
| SCC | Normal 24.0 (20.467,27.533) | 31.0 (27.388,34.612) | | 28.0 (25.076,30.924) | | Abnormal 18.0 (8.368,27.632) | 0.006 | 20.0 (12.242,27.758) | 0.001 |
| NSE | Normal 31.0 (23.192,38.808) | 28.0 (24.052,31.948) | | 29.0 (25.321,32.679) | | Abnormal 17.0 (13.805,20.195) | < 0.001 | 20.0 (16.390,23.610) | < 0.001 |
| EGFR | Mutant 24.0 (8.882,39.118) | 39.0 (16.171,61.829) | | 34.0 (26.573,41.427) | | Not mutant 29.0 (21.958,36.942) | 0.051 | 40.0 (30.651,49.349) | 0.306 |
| Surgery | Yes 60.0 (41.879,78.121) | 69.0 (63.190,74.810) | | 69.0 (61.807,76.193) | | No 18.0 (15.483,28.157) | < 0.001 | 18.0 (16.406,19.394) | < 0.001 |
| Radiotherapy | Yes 23.0 (18.494,27.506) | 33.0 (29.594,36.406) | | 30.0 (27.607,32.393) | | No 24.0 (21.343,26.657) | 0.213 | 20.0 (18.147,21.863) | < 0.001 |
| Chemotherapy | Yes 23.0 (20.444,25.556) | 31.0 (24.720,37.280) | | 29.0 (24.600,33.400) | | No 23.0 (19.368,28.632) | 0.497 | 27.0 (24.482,29.518) | 0.222 |
| Targeted therapy | Yes 24.0 (21.301,26.699) | 28.0 (25.551,30.449) | | 27.0 (25.151,28.849) | | No 21.0 (19.025,22.975) | 0.474 | 26.0 (21.219,30.781) | 0.436 |

Table 3. Univariate analysis of prognostic factors for lung cancer patients by age group.
Clinical factors affecting survival in lung cancer patients. As the Table 3 shown that there was no difference in survival time in the younger group based on tumour location ($P = 0.443$). In contrast, there were significant differences in survival times in the older group according to tumour site ($P = 0.004$). Subsites were not significantly correlated with survival in any of the two groups ($P = 0.174$ and $P = 0.504$).

There were significant differences in survival according to stage in the two groups. The five-year survival rates in the younger group and the older group were as follows: 52.55% and 67.41% with stage I disease ($P < 0.01$), 38.12% and 49.23% with stage II disease ($P = 0.025$), 30.31% and 24.58% with stage III disease ($P = 0.945$), and 7.05% and 7.71% with stage IV disease ($P = 0.451$), respectively. The median survival times for patients with SCLC and NSCLC were 18.0 months and 25.0 months in the younger group and 16.0 months and 31.0 months in the older group, respectively. There were significant differences in the survival times by pathology in both age groups (Table 3).

In the younger group, patients with EGFR mutations had a median survival time of 29.0 months, while those without EGFR mutations had a median survival time of 24 months; the difference was not significant ($P = 0.051$). The same result was found in the older group. With regard to CEA, NSE and SCC, the survival time in the patients with abnormal levels was much lower than that in those with normal levels in the both groups.

Lung cancer patients who underwent surgery had a clearly better prognosis than the younger without surgery in the groups. Young patients who underwent radiotherapy didn't have a better survival outcome than patients without radiotherapy. There was no significant difference in the groups based on whether they underwent chemotherapy or targeted therapy (Table 3).

Cox regression analysis of the prognostic factors in young lung cancer patients. Most patients had missing values for CEA, NSE, SCC, EGFR and subsite; therefore, those variables were excluded from the Cox model. The results are shown in Fig. 3. According to the Cox regression analysis of the younger lung cancer patients, there were five independent factors that affected prognosis, namely, a family history of cancer, symptoms at diagnosis, pathological subtype and surgery. A significantly higher risk of mortality was identified in patients with a family history of cancer ($HR = 1.371, 95\% CI 1.062, 1.768$) and symptoms at diagnosis ($HR = 1.357, 95\% CI 1.031, 1.786$). Advanced stage at diagnosis was also a significant risk factor, with an HR of 1.668 ($95\% CI 1.271, 2.18+$). Surgery ($HR = 0.486, 95\% CI 0.369, 0.640$) was associated with a significantly reduced risk of mortality in younger lung cancer patients. Compared with patients with NSCLC, those with SCLC had an increased risk of mortality ($HR = 1.452, 95\% CI 1.157, 1.822$).
Discussion
Several previous studies have compared clinical features and prognoses between younger and older lung cancer patients. However, the broad category of younger patients encompasses a wide range of subgroups, and different age subgroups of younger patients might have distinctive clinical characteristics and survival outcomes. Therefore, in the context of the dramatic increase in the incidence of lung cancer in the population aged 45 years and older and the relative rarity of patients younger than 45 years old in Hebei Province, according to the cancer registry database, this study was performed to analyse the clinicopathologic characteristics and survival outcomes in the latter population. The results showed that the mortality rate has increased in younger lung cancer patients over the last 40 years, and a family history of cancer, symptoms at diagnosis, advanced stage at diagnosis, adenocarcinoma and no surgical treatment were independent negative prognostic factors in younger lung cancer patients in Hebei Province. As this issue has seldom been addressed, the results of the present study may improve the clinical understanding of the characteristics of younger lung cancer patients.

According to the cancer registry database, Hebei Province has a heavy lung cancer burden, and the incidence has clearly increased over the past 40 years. The ASMR were 10.69 per 100,000, 23.17 per 100,000, 26.64 per 100,000 and 28.15 per 100,000 in 1973–1975, 1990–1992, 2004–2005 and 2010–2015, respectively, with an overall increase of 163.33%. A similar trend was shown in younger patients, with a 30% increase from the 1970s to the 2010s. In addition, there was an obvious increasing trend in the median age at death over the last 40 years, from 38.80 years to 40.88 years, among younger lung cancer patients, which is consistent with the overall trend in age-specific mortality in Hebei Province. This study showed that in the younger age group, the mortality rate was higher in males than in females, according to the data from both the population- and hospital-based databases. Moreover, the PDR was higher in females than in males, according to the data from both the population- and hospital-based databases. This indicates the reliability and stability of the data from these two sources.

In the hospital-based database, we identified several interesting characteristics of younger patients with lung cancer. The proportion of females in the younger group was 50.84%, which was much higher than that in the older group with 34.85%; in addition, in the younger patients, the proportion of females was slightly higher than that of males, which was consistent with some previous related studies. Adenocarcinoma was the most common histological subtype in the younger patients, accounting for 65.27%, which was higher than the proportion in the older group. SCLC and squamous cell carcinoma were the second and third most common subtypes in the younger group, respectively, which was similar to the results in several articles from China, but inconsistent with the results from other countries. squamous cell carcinoma and SCLC ranked the second and third most common subtype in the younger group. A relatively high percentage of patients had advanced-stage disease at diagnosis in our study (greater than 50% of all patients), which was consistent with previous studies.

The correlation between age and genetic abnormalities is controversial. According to several studies, there is a trend towards a greater proportion of older patients harbouring EGFR mutations. However, other studies reported the opposite result. Sacher et al. found that younger patients had higher frequencies of driver mutations than older patients in a Caucasian population (EGFR mutations: 32% vs 23%) in another study by Scarpino et al., they mentioned that the frequency of EGFR driver mutations was 23% in younger patients, which was higher than the 16% in older patients. In our current study, among the lung cancer patients who underwent testing for EGFR mutations, 49.10% had mutations in the younger group, and 44.81% had mutations in the older group; the difference was not significant, which was consistent with a recent study in Chinese patients. CEA is one of the most widely used tumour markers, and elevated CEA expression is often observed in patients with lung cancer, especially those with adenocarcinoma. SCC has been confirmed to be closely related to the prognosis of lung cancer. Some studies have suggested that the level of SCC in exhaled breath condensate might serve as a marker that could be used as an early diagnosis of lung cancer. NSE is currently the most reliable tumour marker, and it is used for the diagnosis, prognostic prediction and follow-up monitoring of small-cell lung cancer. However, the expression levels of serum biomarkers have rarely been reported in younger lung cancer patients in previous studies. Therefore, our current study investigated the relationships between these three tumour markers and patient age. There were no significant differences between the two age groups with regard to CEA and SCC. Interestingly, the level of expression of NSE was much higher in the younger group than that in the older group, which was consistent with the study by Yu et al. although the cut-off age in that study was 60 years old.

In previous studies, there was a significant difference in the smoking rate between younger and older lung cancer patients. In our study, 28.83% of the younger group smoked, which is lower than the proportions reported internationally, such as in Japan (47.4–66%) and the USA (80–93%). Nevertheless, the proportion of smokers in our study is consistent with those reported in Liu’s and Hou’s studies, with the proportions of lung cancer patients who were smokers reported as 28.40% and 28.81% in China, respectively. In contrast, the proportion in our study was higher than that in the study by Laurence et al., which reported that approximately 14.0% of the lung cancer patients younger than 40 years old in France and Peru were smokers. A family history of cancer was regarded as a surrogate for a genetic predisposition for lung cancer in some previous studies. The proportions of patients with a family history of cancer differed between younger and older patients. Our current study found a relatively high proportion of family history of cancer in younger lung cancer patients, this finding is consistent with the findings of previous studies. A Polish study suggested that patients younger than 50 years old were relatively more likely than their older counterparts to have had a mother who had had lung cancer (4.7% vs 3.0%; P < 0.001) and to have had a father who had had lung cancer (7.6% vs 4.1%; P < 0.001). Another study by Laurence et al. reported that the relatives of 25% of the younger patients who had a family history of lung cancer had developed the disease before they were 45 years old, compared to less than 5% in the old group. One study by Abbasowa et al. reported that the proportions of the younger and older groups of patients who had a family history of cancer were 44.8% and 36.0%, respectively, and the difference was statistically significant. In
contrast, other studies by Wei et al. and Anna et al. reported that although the proportion in younger individuals was slightly higher than that in older individuals, the difference was not significant13,24. Symptoms, including cough, thoracic pain and tightness, at diagnosis are common. However, a previous study reported that younger patients were more frequently asymptomatic at diagnosis, while older patients were significantly more likely to have thoracic pain, cough and fatigue (p < 0.01)40. The proportions of younger and older patients with symptoms at diagnosis according to the data from the hospital-based database in Hebei Province were roughly similar to those in other countries.

According to the literature, smoking is regarded as a major and most well-established risk factor and independent prognostic factor for lung cancer41. A previous study suggested that an estimated 75.04% of lung-cancer-related deaths in men and 18.35% in women are attributable to tobacco use in China62. In agreement with these findings, our study found that the survival time for patients who smoked was shorter than that for patients who had never smoked in the younger group. This finding was consistent with the study by Ayesha et al., which reported that a Kaplan–Meier survival analysis showed that smoking status significantly impacted survival63. A family history of cancer was found to be an independent prognostic factor in younger lung cancer patients in the current study. This finding has already been reported in some studies, such as that by Ganti et al. Multivariate Cox regression showed that patients with a family history of cancer had an HR for mortality of 1.371 (95% CI 1.062, 1.768) compared to those without a family history of cancer, which was consistent with a US study that found an adjusted hazard ratio for mortality of 1.65 in the group with a family history of lung cancer compared with the group without such a family history64. A previous study in Japan demonstrated that inherited genetic susceptibility, as reflected in the family history, may contribute to the development of lung cancer45. However, the adjusted hazard ratio for death was not significant in the older group of patients, which may be because relatively few patients had a family history of cancer in the older group.

There have been conflicting findings regarding about the survival and prognosis of younger patients with lung cancer. Perhaps due to the differences in the cut-off age or use of surgery in the various populations of younger lung cancer patients, the findings have varied across studies13,37,42,43,54,57,63,65,66. In our study, the survival time for younger patients was relatively worse than that for older patients. There are some explanations for this finding. The clinical stage at diagnosis is well known to be the most important predictor of survival, and the proportion of patients with advanced-stage disease was higher in the younger group than in the older group (P < 0.001). It has been suggested that lung cancer tends to be more aggressive in nature, to have a more rapid development or to be the result of underlying genetic predispositions in younger patients43,45,47. Younger patients with lung adenocarcinoma, especially those with advanced-stage disease, did not have significantly better overall survival than older patients despite undergoing more aggressive treatment41. On the other hand, because younger patients are more frequently asymptomatic at diagnosis, it is possible that younger patients are less likely to suspect cancer, which may result in diagnostic and surgical delays, resulting in disease progression43. Other factors (e.g., late diagnosis, disease awareness, and financial challenges) represent potential contributors to or alternative explanations of this phenomenon13.

The conflicting results suggest that there is considerable heterogeneity among younger adults with lung cancer. Large-scale, multicenter, and nationally representative data are urgently needed to fully explore the characteristics and prognosis of lung cancer in younger patients and to determine the most effective interventions34. For younger individuals, especially individuals who have a family history of cancer, a history of smoking, symptoms (such as cough, chest pain, haemoptysis) or abnormal biomarker levels, regular screening for lung cancer is recommended, and it is necessary to seek medical assistance promptly.

Limitations
In interpreting these findings, several limitations inherent to this study must be considered. The older lung cancer patients included in this study were selected randomly from the entire age group, introducing the possibility of referral bias. The second limitation is that only a relatively small number of patients underwent EGFR mutation analysis because at the time of this study, this test was not mandatory in China. Furthermore, due to the retrospective nature of the data collection, we were not able to analyse potentially prognostic variables, such as environmental factors, occupational exposure to carcinogens, other gene mutations, family financial status, and novel cancer therapies, which might be of prognostic value in lung cancer patients.

Conclusion
In conclusion, our study indicates that younger patients with lung cancer have distinctive characteristics, including a higher percentage of female patients, family history of cancer, more adenocarcinoma and more advanced stage at diagnosis. We noticed that younger lung cancer patients appear to trend a worse prognosis. A family history of cancer, symptoms at diagnosis, pathology, stage at diagnosis and surgery were confirmed as independent prognostic factors in younger lung cancer patients. Therefore, for younger individuals, especially the individuals who have a family history of cancer, smoking, symptoms (such as cough, chest pain, haemoptysis) or abnormal biomarker levels, regular screening for lung cancer is recommended. In addition, considering the conflicting results with regard to younger patients, large-scale, multicentre, and nationally representative data are urgently needed to fully explore characteristics and prognosis of lung cancer in younger patients and to determine the most effective interventions.

Received: 9 October 2020; Accepted: 8 March 2021
Published online: 25 March 2021
References

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
2. Liu, S. et al. Incidence and mortality of lung cancer in China, 2008–2012. Chin. J. Cancer Res. 30(6), 580–587 (2018).
3. Cao, M. & Chen, W. Epidemiology of lung cancer in China. Thorac. Cancer. 10(1), 3–7 (2019).
4. Zeng, H. et al. Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Glob. Health. 6(5), e555–e567 (2018).
5. Chen, W. Q. et al. Lung cancer incidence and mortality in China in 2013. Zhonghua zhong liu za zhi [Chin. J. Oncol.]. 39(10), 795–800 (2017).
6. He, Y. et al. Cancer incidence and mortality in Hebei province, 2013. Medicine 96(26), e7293 (2017).
7. Chinese Preventive Medicine A. [Lung cancer screening guideline of China (T/CPCMA 013-2020)]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2021;43(1):1–7.
8. Smith, R. A. et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 66(2), 96–114 (2016).
9. Schabath, M. B. & Aberle, D. R. MILD trial, strong confirmation of lung cancer screening efficacy. Nat. Rev. Clin. Oncol. 16(9), 529–530 (2019).
10. Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115–132 (2016).
11. Ye, T. et al. Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. J Thorac. Dis. 6(10), 1396–1402 (2014).
12. Mantilla MGNRRJAPKRR. Lung Cancer in the Young. Lung. 2020;198(1):195–200.
13. Sacher, A. G. et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2(3), 313–320 (2016).
14. Subramanian, J. et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: A surveillance, epidemiology, and end results (SEER) analysis. J. Thorac. Oncol. 8(1), 23–28 (2013).
15. Thomas, A., Chen, Y., Yu, T., Jakopovic, M. & Giaccione, G. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front. Oncol. 5, 113 (2015).
16. He, CH, Shih JF, Lai SL, Chen YM. Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder. J Chin Med Assoc. 2020.
17. Ho, C. H. et al. Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget. 7(29), 46628–46635 (2016).
18. Tanaka, K. et al. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Cancer Am. Cancer Soc. 123(10), 1731–1740 (2017).
19. Tian, D. L. et al. Surgery for young patients with lung cancer. Lung Cancer 42(2), 215–220 (2003).
20. Minami, H., Yoshimura, M., Matsuoka, H., Toshikazu, S. & Tsubota, N. Lung cancer treated surgically in patients <50 years of age. Chest 120(1), 32–36 (2001).
21. Hanagiri, T. et al. Results of surgical treatment for lung cancer in young adults. Int. Surg. 93(1), 50–54 (2008).
22. Kamiyama, I., Watanabe, M., Horinouchi, H., Kawamura, M. & Kobayashi, K. Surgical analysis for lung cancer in patients younger than 40 years of age. Lung Cancer 49, S33 (2005).
23. Bigay-Game, L. et al. Characteristics of lung cancer in patients younger than 40 years: A prospective multicenter analysis in France. Oncol.-Basel. 95(6), 337–343 (2018).
24. Yoshida, K. et al. Association between family history of cancer and lung cancer risk among Japanese men and women. Toboka J. Exp. Med. 247(2), 99–110 (2019).
25. Zhao, W. et al. Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer. Int. J. Clin. Exp. Pathol. 8(8), 9506–9511 (2015).
26. Liu, C. X. et al. A combination of tumor and molecular markers predicts a poor prognosis in lung adenocarcinoma. Int. J. Clin. Exp. Pathol. 12(5), 1690–1701 (2019).
27. Office for Cancer Prevention, Control, Ministry of Health, P.R. China. Malignant Tumor Mortality Survey Report 1st edn. (People's Medical Publishing House, 1980).
28. Zhang, G. S., He, Y. T. & Hou, J. The geographical distribution of cancer death in Hebei province 1990–1992. Chin. Cancer 7, 5–21 (1998).
29. Office for Cancer Prevention, Control, Ministry of Health, P.R. China. Malignant Tumor Mortality Survey Report (2004–2005) 1st edn. (People's Medical Publishing House, 2007).
30. Li, D., Xu, X., Liu, J., Liang, D. Shi, J. L. et al. Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008–2017). Thoracic cancer. 2020.
31. He, Y. T. et al. Lung cancer burden has increased during the last 40 years in Hebei Province, China. Thorac. Cancer. 7(3), 323–332 (2016).
32. Liang, D. et al. Trends and patterns of cancer mortality in North China (Hebei Province), 1973–2013. Sci. Rep. 8(1), 311 (2018).
33. Corrales-Rodriguez, L. et al. An international epidemiological analysis of young patients with non-small cell lung cancer (AdulKey-CLICap), Lung Cancer 113, 30–36 (2017).
34. Liu, B. et al. Lung cancer in young adults aged 35 years or younger: A full-scale analysis and review. J. Cancer. 10(15), 3553–3559 (2019).
35. Jemal, A. et al. Higher lung cancer incidence in young women than young men in the United States. N. Engl. J. Med. 378(21), 1999–2009 (2018).
36. Gu, C. et al. Sublobar resection versus lobectomy in patients aged <15 years with stage IA non-small cell lung cancer: a SEER database analysis. J. Cancer Res. Clin. Oncol. 143(11), 2375–2382 (2017).
37. Jiang, W. et al. Comparisons of multiple characteristics between young and old lung cancer patients. Chin. Med. J. Peking. 125(1), 72–80 (2012).
38. Sheyhidin, I. et al. Clinical analysis of 99 young patients with lung cancer in different nationalities in Xinjiang[1]. Zhongguo Fei Ai Za Zhi 7(6), 512–514 (2004).
39. Garrara, S. H. et al. Clinical and imaging features of non-small-cell lung cancer in young patients. Clin. Lung Cancer. 22(1), 23–31 (2021).
40. Catania, C. et al. Molecular features and clinical outcomes of lung malignancies in very young people. Future Oncol. 11(8), 1211–1221 (2015).
41. Igata, F., Uchino, I., Fujita, M., Iwasaki, A. & Watanabe, K. Clinical features of lung cancer in Japanese patients aged under 50. Asian Pac. J. Cancer Prevent. APJCP 17(7), 3377–3380 (2016).
42. Inoue, M. et al. Clinicopathological characteristics and surgical results of lung cancer patients aged up to 50 years: The Japanese Lung Cancer Registry Study 2004. Lung Cancer 83(2), 246–251 (2014).
43. Toneyama, R. et al. Clinicopathological characteristics and treatment strategies for young lung cancer patients. Ann. Transl. Med. 7(5), 100 (2019).
44. Ueno, T. et al. Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer 78(3), 207–211 (2012).
45. Zhang, Y. et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. *Clin. Cancer Res.* 18(7), 1947–1953 (2012).

46. Hou, H. et al. Comprehensive molecular characterization of young Chinese patients with lung adenocarcinoma identified a distinctive genetic profile. *Oncologist.* 23(9), 1008–1015 (2018).

47. Pan, X., Lv, T. Z. F., Fan, H., Liu, H. & Song, Y. Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger. *Clin. Transl. Oncol.* 20(9), 1168–1174 (2018).

48. Scarponi, S. et al. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adolescents and young adults. *Lung Cancer* 97, 95–98 (2016).

49. Wang, X. et al. Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer. *J. Clin. Lab. Anal.* 32(8), e22565 (2018).

50. Yang, P. et al. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adolescents and young adults. *Lung Cancer* 97, 95–98 (2016).

51. Yu, D., Du, K., Liu, T. & Chen, G. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients. *Int. J. Mol. Sci.* 14(6), 11145–11156 (2013).

52. Zou, Y. et al. CEA, SCC and NSE levels in exhaled breath condensate—possible markers for early detection of lung cancer. *J. Breath Res.* 7(4), 047101 (2013).

53. Dal Bello, M. G. et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. *J. Transl. Med.* 17(1), 74 (2019).

54. Suidan, A. M. et al. Lung cancer in young patients: Higher rate of driver mutations and brain involvement, but better survival. *J. Glob. Oncol.* 5, 1–8 (2019).

55. Gadgeel, S. M. et al. Lung cancer in patients < 50 years of age: The experience of an academic multidisciplinary program. *Chest* 115(5), 1232–1236 (1999).

56. Sekine, I., Nishiwaki, Y. Y. T., Nagai, K., Suzuki, K. & Kodama, T. Young lung cancer patients in Japan: different characteristics between the sexes. *Ann. Thorac. Surg.* 67(5), 1451–1455 (1999).

57. Galvez-Nino, M. et al. Lung cancer in the young. *Lung* 198(1), 195–200 (2020).

58. Radzikowska, E., Roszkowski, K. & Glaz, P. Lung cancer in patients under 50 years old. *Lung Cancer* 33(2–3), 203–211 (2001).

59. Alm, P. H. Lung cancer in younger patients. *Dan. Med. J.* 63(7), A5248 (2016).

60. Mauri, D. et al. Non-small cell lung cancer in the young: A retrospective analysis of diagnosis, management and outcome data. *Anticancer Res.* 26(4B), 3175–3181 (2006).

61. Liang, D. et al. Lung cancer in never-smokers: A multicenter case-control study in North China. *Front. Oncol.* 9, 1354 (2019).

62. Wang, J. B. et al. Attributable causes of lung cancer incidence and mortality in China. *Thorac. Cancer.* 2(4), 156–163 (2011).

63. Bryant, A. S. & Cerfolio, R. J. Differences in outcomes between younger and older patients with non-small cell lung cancer. *Ann. Thorac. Surg.* 85(5), 1735–1739 (2008).

64. Ganti, A. K., Loberiza, F. R. Jr. & Kessinger, A. Association of positive family history with survival of patients with lung cancer. *Lung Cancer* 63(1), 136–139 (2009).

65. Xia, W. et al. Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death. *Cancer Manag. Res.* 10, 41–48 (2018).

66. Yang, S., Song, Z. & Cheng, G. Genomic alterations and survival in young patients aged under 40 years with completely resected non-small cell lung cancer. *Ann. Transl. Med.* 7(7), 140 (2019).

67. Yang, P., Bamlet, W. R., Ebbert, J. O., Taylor, W. R. & de Andrade, M. Glutathione pathway genes and lung cancer risk in young and old populations. *Carcinogenesis* 25(10), 1935–1944 (2004).

Acknowledgements

We thank The Fourth Hospital of Hebei Medical University (Shijiazhuang, China) and Office of Cancer Prevention and Control of Hebei Provincial for their generous help.

Author contributions

Y.H. and J.S. conceived of the idea, designed the study, analyzed and interpreted data and wrote the manuscript. J.S., D.L. and L.D. performed the followed up, confirmed statistical analyses and draw the figures. J.S. revised the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Y.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021